269 related articles for article (PubMed ID: 11473648)
1. Mycophenolate mofetil combined with a cyclooxygenase-2 inhibitor ameliorates murine lupus nephritis.
Zoja C; Benigni A; Noris M; Corna D; Casiraghi F; Pagnoncelli M; Rottoli D; Abbate M; Remuzzi G
Kidney Int; 2001 Aug; 60(2):653-63. PubMed ID: 11473648
[TBL] [Abstract][Full Text] [Related]
2. Mycophenolate mofetil limits renal damage and prolongs life in murine lupus autoimmune disease.
Corna D; Morigi M; Facchinetti D; Bertani T; Zoja C; Remuzzi G
Kidney Int; 1997 May; 51(5):1583-9. PubMed ID: 9150476
[TBL] [Abstract][Full Text] [Related]
3. Effect of mycophenolate mofetil on severity of nephritis and nitric oxide production in lupus-prone MRL/lpr mice.
Lui SL; Tsang R; Wong D; Chan KW; Chan TM; Fung PC; Lai KN
Lupus; 2002; 11(7):411-8. PubMed ID: 12195781
[TBL] [Abstract][Full Text] [Related]
4. Inhibition of cyclooxygenases reduces complement-induced glomerular epithelial cell injury and proteinuria in passive Heymann nephritis.
Takano T; Cybulsky AV; Cupples WA; Ajikobi DO; Papillon J; Aoudjit L
J Pharmacol Exp Ther; 2003 Apr; 305(1):240-9. PubMed ID: 12649375
[TBL] [Abstract][Full Text] [Related]
5. Distinct effects of mycophenolate mofetil and cyclophosphamide on renal fibrosis in NZBWF1/J mice.
Yung S; Zhang Q; Chau MK; Chan TM
Autoimmunity; 2015; 48(7):471-87. PubMed ID: 26099989
[TBL] [Abstract][Full Text] [Related]
6. Mycophenolate mofetil alleviates lupus nephritis through urokinase receptor signaling in a mice model.
Cheng CC; Lee YF; Lan JL; Wu MJ; Hsieh TY; Lin NN; Wang JM; Chiu YT
Lupus; 2013 May; 22(6):554-61. PubMed ID: 23478030
[TBL] [Abstract][Full Text] [Related]
7. Bindarit retards renal disease and prolongs survival in murine lupus autoimmune disease.
Zoja C; Corna D; Benedetti G; Morigi M; Donadelli R; Guglielmotti A; Pinza M; Bertani T; Remuzzi G
Kidney Int; 1998 Mar; 53(3):726-34. PubMed ID: 9507220
[TBL] [Abstract][Full Text] [Related]
8. Comparison of therapeutic efficacy between bortezomib and combination treatment of prednisolone and mycophenolate mofetil on nephritis in NZB/WF1 mice.
Lee SW; Kim BS
Clin Exp Rheumatol; 2010; 28(3):393-6. PubMed ID: 20497633
[TBL] [Abstract][Full Text] [Related]
9. Different effect of cyclosporine A and mycophenolate mofetil on passive Heymann nephritis in the rat.
Blume C; Heise G; Hess A; Waldner C; Grabensee B; Schroer K; Heering P
Nephron Exp Nephrol; 2005; 100(2):e104-12. PubMed ID: 15855806
[TBL] [Abstract][Full Text] [Related]
10. Biochemical and pharmacological profile of a tetrasubstituted furanone as a highly selective COX-2 inhibitor.
Riendeau D; Percival MD; Boyce S; Brideau C; Charleson S; Cromlish W; Ethier D; Evans J; Falgueyret JP; Ford-Hutchinson AW; Gordon R; Greig G; Gresser M; Guay J; Kargman S; Léger S; Mancini JA; O'Neill G; Ouellet M; Rodger IW; Thérien M; Wang Z; Webb JK; Wong E; Chan CC
Br J Pharmacol; 1997 May; 121(1):105-17. PubMed ID: 9146894
[TBL] [Abstract][Full Text] [Related]
11. Anti-DNA antibody induction of protein kinase C phosphorylation and fibronectin synthesis in human and murine lupus and the effect of mycophenolic acid.
Yung S; Zhang Q; Zhang CZ; Chan KW; Lui SL; Chan TM
Arthritis Rheum; 2009 Jul; 60(7):2071-82. PubMed ID: 19565476
[TBL] [Abstract][Full Text] [Related]
12. 15-Deoxyspergualin and cyclophosphamide, but not mycophenolate mofetil, prolong survival and attenuate renal disease in a murine model of ANCA-associated crescentic nephritis.
Birck R; Newman M; Braun C; Neumann I; Nemoto K; Yard B; Waldherr R; van der Woude FJ
Nephrol Dial Transplant; 2006 Jan; 21(1):58-63. PubMed ID: 16141461
[TBL] [Abstract][Full Text] [Related]
13. The effects of a thromboxane synthase inhibitor, a prostacyclin analog and PGE1 on the nephritis of the NZB/W F1 mouse.
Clark WF; Parbtani A; McDonald JW; Taylor N; Reid BD; Kreeft J
Clin Nephrol; 1987 Dec; 28(6):288-94. PubMed ID: 2450713
[TBL] [Abstract][Full Text] [Related]
14. Effect of flosulide, a selective cyclooxygenase 2 inhibitor, on passive heymann nephritis in the rat.
Blume C; Heise G; Mühlfeld A; Bach D; Schrör K; Gerhardz CD; Grabensee B; Heering P
Kidney Int; 1999 Nov; 56(5):1770-8. PubMed ID: 10571785
[TBL] [Abstract][Full Text] [Related]
15. Mycophenolate mofetil reduces renal cortical inducible nitric oxide synthase mRNA expression and diminishes glomerulosclerosis in MRL/lpr mice.
Yu CC; Yang CW; Wu MS; Ko YC; Huang CT; Hong JJ; Huang CC
J Lab Clin Med; 2001 Jul; 138(1):69-77. PubMed ID: 11433230
[TBL] [Abstract][Full Text] [Related]
16. Effects of specific inhibition of cyclo-oxygenase-1 and cyclo-oxygenase-2 in the rat stomach with normal mucosa and after acid challenge.
Gretzer B; Maricic N; Respondek M; Schuligoi R; Peskar BM
Br J Pharmacol; 2001 Apr; 132(7):1565-73. PubMed ID: 11264251
[TBL] [Abstract][Full Text] [Related]
17. Attenuation of murine lupus nephritis by mycophenolate mofetil.
Van Bruggen MC; Walgreen B; Rijke TP; Berden JH
J Am Soc Nephrol; 1998 Aug; 9(8):1407-15. PubMed ID: 9697662
[TBL] [Abstract][Full Text] [Related]
18. Development of a novel Poly (I:C)-induced murine model with accelerated lupus nephritis and examination of the therapeutic effects of mycophenolate mofetil and a cathepsin S inhibitor.
Kawato Y; Fukahori H; Nakamura K; Kubo K; Hiramitsu M; Kinugasa F; Morokata T
Eur J Pharmacol; 2023 Jan; 938():175440. PubMed ID: 36463947
[TBL] [Abstract][Full Text] [Related]
19. Lupus nephritis: treatment with mycophenolate mofetil.
Kapitsinou PP; Boletis JN; Skopouli FN; Boki KA; Moutsopoulos HM
Rheumatology (Oxford); 2004 Mar; 43(3):377-80. PubMed ID: 14963204
[TBL] [Abstract][Full Text] [Related]
20. Imatinib ameliorates renal disease and survival in murine lupus autoimmune disease.
Zoja C; Corna D; Rottoli D; Zanchi C; Abbate M; Remuzzi G
Kidney Int; 2006 Jul; 70(1):97-103. PubMed ID: 16688113
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
